Concomitant medications will be reviewed and any new medications recorded 3. QoL (FACT -P, BPI -SF and EQ -5D-3L) where translations are available 4. Abbreviated physical exam, consisting of VS, temperature, and weight. Only significant changes in PE from Screening will be re corded. 5. ECOG performance status 6. Immune monitoring assessments are to be collected prior to first dose only after a subject is deemed eligible for the study by all other criteria. Blood sample collection will include: a. Serum for immune and biomarker status b. Peripheral blood RNA//biomarker analysis c. Immune functional assay ( ) d. CTC quantification ( ) 7. Blood samples will be obtained for: a. Hematology (CBC with differential, RBC with indices, platelet count) Protocol BNIT -PRV- 301; Amendment 7 PROSTVAC -V/F Version 2.7, 08 February 2017 CONFIDENTIAL AND RESTRICTED 47 Amend 7 Disclosure requires written consent from Bavarian Nordic , Inc. b. Serum Chemistry (BUN, creatinine, ALT, AST, alkaline phosphatase, total bilirubin, LDH, sodium, potassium, chloride, bicarbonate, calcium and glucose). c.